Literature DB >> 28396200

Nasal highflow eliminates CO2 from lower airways.

Jens Bräunlich1, Friederike Goldner2, Hubert Wirtz3.   

Abstract

INTRODUCTION: Nasal highflow (NHF) has a growing evidence in treatment of hypoxemic respiratory failure. There are preliminary data available about use in acute and chronic type-II-respiratory failure. Unfortunately underlying mechanisms of NHF are not well understood. Increase in airway pressure seems too small to explain the observed reduction in hypercapnia. Most interesting effects are wash-out of upper airways and reduction of functional dead space. There are no data available about a wash-out of lower airways.
METHODS: We established a sheep lung model to evaluate CO2-wash-out in lower airways. Therefore we placed measuring and insufflation catheter in maximal expanded lung. The lung was not ventilated in order to minimize influence of CO2 rebreathing and increase in airway pressure. Airway pressure and CO2 values were measured in lower airways and in tracheal space.
RESULTS: CO2 was decreased by NHF in lower airways and in tracheal space. Changes in CO2 were flow dependent. There was also an increase in airway pressure in these settings.
CONCLUSIONS: NHF is able to decrease CO2 in lower airways in a flow-dependent manner. This effect is independent of an increase in airway pressure and CO2-rebreathing. So wash-out is an important reason for efficiency of NHF in decreasing hypercapnia.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hypercapnia; NHF; Nasal highflow; Type-II-respiratory failure; Wash-out

Mesh:

Substances:

Year:  2017        PMID: 28396200     DOI: 10.1016/j.resp.2017.03.012

Source DB:  PubMed          Journal:  Respir Physiol Neurobiol        ISSN: 1569-9048            Impact factor:   1.931


  5 in total

1.  Effectiveness of nasal highflow in hypercapnic COPD patients is flow and leakage dependent.

Authors:  Jens Bräunlich; Friederike Mauersberger; Hubert Wirtz
Journal:  BMC Pulm Med       Date:  2018-01-24       Impact factor: 3.317

2.  [Position Paper for the State of the Art Application of Respiratory Support in Patients with COVID-19 - German Respiratory Society].

Authors:  M Pfeifer; S Ewig; T Voshaar; W Randerath; T Bauer; J Geiseler; D Dellweg; M Westhoff; W Windisch; B Schönhofer; S Kluge; P M Lepper
Journal:  Pneumologie       Date:  2020-04-22

3.  Nasal high-flow versus noninvasive ventilation in patients with chronic hypercapnic COPD.

Authors:  Jens Bräunlich; Dominic Dellweg; Andreas Bastian; Stephan Budweiser; Winfried Randerath; Dora Triché; Martin Bachmann; Christian Kähler; Abdel Hakim Bayarassou; Irmhild Mäder; Jens Geiseler; Norbert Köhler; David Petroff; Hubert Wirtz
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-07-05

Review 4.  The Mechanisms of Benefit of High-Flow Nasal Therapy in Stable COPD.

Authors:  Massa Zantah; Aloknath Pandya; Michael R Jacobs; Gerard J Criner
Journal:  J Clin Med       Date:  2020-11-26       Impact factor: 4.241

5.  Nasal high-flow compared to non-invasive ventilation in treatment of acute acidotic hypercapnic exacerbation of chronic obstructive pulmonary disease-protocol for a randomized controlled noninferiority trial (ELVIS).

Authors:  Jens Bräunlich; Nicole Köppe-Bauernfeind; David Petroff; Annegret Franke; Hubert Wirtz
Journal:  Trials       Date:  2022-01-10       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.